Curzion Pharmaceuticals
Curzion was developing a compound for Diffuse cutaneous systemic sclerosis (dcSSc), a rare, chronic autoimmune disease marked by fibrosis, or skin thickening, in areas including hands, forearms, upper arms and thighs.
The compound was approaching phase 2b studies.
